World
China
China
China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by t…
Continue Reading on South China Morning Post
This article is aggregated from South China Morning Post. Click below to read the full story.
